Please wait
AbbVie Inc. (ABBV) is listed on the Nigerian Exchange in the Healthcare sector, with exposure to Drug Manufacturers - General. This page brings together the current share price, valuation, dividend context, business summary, and a practical current view so you can assess the stock faster.
Healthcare
₦671T
2.7%
124.80
Current price
₦380,025.00
Updated Updated just now
Conviction
69/100
Confidence
Low
Market tone
neutral · 69/100
Entry
Medium · 69/100
Recent price action for ABBV, so the page starts with the stock itself before the deeper analysis.
Both size and absolute trading activity suggest this name is usually easier to enter and exit.
Valuation view
Priced richer than peers
Income view
Low income profile
Market tone
neutral (69/100) — price action, attention, and recent context all lean here.
Entry view
Medium (69/100) — The company is profitable on the latest reported numbers.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Investors usually follow ABBV for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Director dealings
0
Reported buys, sells, and mixed dealings.
Corporate actions
0
Dividend and company notices.
Market events
0
Insider, filing, dividend, and price events.
Source records
3
Captured updates we can trace.
Whisone is bullish because fundamentals are solid at 69/100 while RSI is hot at 76.5. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
ROE
-54.5%
Return on equity
ROA
10.0%
Return on assets
Debt / equity
-11.03
Lower is usually safer.
P/B ratio
-3.77
Useful for book value support.
Dividend yield
2.7%
Current income signal.
99/100
Direction
Positive bias
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Trading liquidity looks supportive for the forecast to transmit into price action.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
₦397,995.00
Analyst view
Buy
Analyst target
₦381,570.00
Forecast refresh
Updated 2 min ago
Quality score
74
Growth score
65.75
These are the external analyst numbers and business outlook figures already synced into the company record.
Low target
₦98,399,999,999,999.98
High target
₦101,550,000,000,000.00
Revenue this year
₦101T
Revenue next year
₦109T
EPS this year
₦21,375.00
EPS next year
₦24,435.00
Dividend / share
₦7,965.00
Forward P/E
10.04
US stock catalog seed
Updated 2d ago
Seeded from the built-in US stock catalog for database discovery and later background refresh.
Price points saved
50
Latest market date
2026-06-26
Dividend yield
2.7%
Ex-dividend date
Jul 15, 2026
ABBV
AbbVie Inc.
Price: ₦380,025.00
P/E: 124.8
Yield: 2.7%
ABT
Abbott Laboratories
Price: ₦141,180.00
P/E: 26.36
Yield: 2.7%
AMGN
Amgen Inc.
Price: ₦537,495.00
P/E: 24.94
Yield: 2.8%
BMY
Bristol-Myers Squibb Company
Price: ₦86,280.00
P/E: N/A
Yield: N/A
Industry
Drug Manufacturers - General
Founded
2012
Employees
57,000
Exchange
NYSE
Ticker
ABBV
